Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$155.04 USD

155.04
7,145,777

-0.43 (-0.28%)

Updated Nov 11, 2024 04:00 PM ET

After-Market: $155.14 +0.10 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 249)

Industry: Large Cap Pharmaceuticals

Zacks News

CVS Health (CVS) Q1 Earnings Surpass Estimates, EPS View Cut

CVS Health's (CVS) robust sales growth across all three operating segments drives top-line results.

DENTSPLY SIRONA (XRAY) Q1 Earnings & Revenues Beat Estimates

DENTSPLY SIRONA's (XRAY) Q1 earnings and revenues decline year over year, driven by the unfavorable foreign currency movement and soft demand across all geographical segments.

Penumbra (PEN) Q1 Earnings Top Estimates, Sales Remain Robust

Penumbra's (PEN) sales during the first quarter reflect continued demand for its products. The 2023 outlook is encouraging as earnings improve despite macro challenges.

Omnicell (OMCL) Q1 Earnings Top Estimates, Margins Down

Despite a year-over-year decrease, Omnicell's (OMCL) first-quarter revenues and earnings exceed the top end of the previously announced outlook amid an uncertain macroeconomic environment.

Zimmer Biomet (ZBH) Q1 Earnings Beat Estimates, View Raised

Each of Zimmer Biomet's (ZBH) geographic segments and product divisions records strong year-over-year sales growth at CER.

Hologic's (HOLX) Q2 Earnings Beat Estimates, 2023 View Up

The year-over-year growth in Breast Health and GYN Surgical Businesses contributed to Hologic's (HOLX) Q2 revenues.

IDEXX (IDXX) Q1 Earnings Beat Estimates, Margins Increase

Continued solid demand for veterinary services and record global premium instrument placements drive IDEXX's (IDXX) Q1 revenues.

Merit Medical (MMSI) Tops Q1 Earnings Estimates, Ups FY23 View

Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the first quarter.

Kinjel Shah headshot

Pharma Stock Roundup: MRK & Others Post Q1 Results, LLY Drug Shines in Obesity Study

Merck (MRK), Eli Lilly (LLY), AstraZeneca (AZN) and others report first-quarter results. J&J (JNJ) provides an update on the IPO of its Consumer Health segment, Kenvue.

Integer Holdings (ITGR) Q1 Earnings, Revenues Beat Estimates

Integer Holdings' (ITGR) first-quarter results reflect robust Medical and Non-Medical sales, besides strength in all the product lines.

Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates

ResMed (RMD) reports a solid third-quarter top line, led by strong device sales growth through steady production and delivery of its cloud-connected flow generator devices to meet high market demand.

Eli Lilly (LLY) Q1 Earnings Miss, Sales Beat, '23 View Raised

Eli Lilly (LLY) reports mixed results for the first quarter of 2023, missing estimates for earnings while beating the same for revenues. Management raises the 2023 outlook.

AbbVie (ABBV) Q1 Earnings Beat, Skyrizi Sales Underperform

AbbVie's (ABBV) first-quarter 2023 earnings and sales beat estimates. However, share price dives as some key drugs miss sales estimates.

Accuray (ARAY) Q3 Earnings and Revenues Surpass Estimates

Accuray (ARAY) reports a solid fiscal third-quarter top line on the back of robust segmental performances.

AstraZeneca (AZN) Q1 Earnings Beat, COVID Products Hurt Sales

AstraZeneca (AZN) beats first-quarter estimates for earnings while missing the same for sales. The company reaffirms its 2023 guidance.

Nevro (NVRO) Q1 Earnings and Revenues Surpass Estimates

Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q1, partly owing to robust domestic performance.

Surmodics (SRDX) Q2 Earnings Top Estimates, FY23 View Revised

Surmodics (SRDX) reports a solid fiscal second-quarter top line on the back of robust Medical Device revenues.

Chemed (CHE) Lags Q1 Earnings Estimates, Reaffirms Guidance

Strength in the VITAS and Roto-Rooter branches contributes to Chemed's (CHE) first-quarter top line.

Alkermes (ALKS) Q1 Earnings & Revenues Beat Estimates

Alkermes (ALKS) reports encouraging first-quarter results, wherein both earnings and revenues beat estimates. This is due to strong growth in commercial execution of its proprietary products, Lybalvi and Vivitrol.

GSK Beats on Q1 Earnings, Lags Sales, Reaffirms 2023 Outlook

Though GSK's revenues benefit from strong growth across all segments, the declining COVID-19 antibody sales do not bode well. Management reaffirms its 2023 guidance.

AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?

AbbVie's (ABBV) Q1 performance will likely reflect declining sales of Humira following the loss of exclusivity. Sales of Rinvoq and Skyrizi are expected to partially offset this fall.

Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It

Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Ekta Bagri headshot

4 Pharma, Biotech Stocks Poised to Beat Q1 Earnings Estimates

We look at a few pharma/biotech companies, SNY, AMGN, REGN, ACAD, which are poised to beat on earnings in the first quarter.

Is ALPS O'Shares U.S. Quality Dividend ETF (OUSA) a Strong ETF Right Now?

Smart Beta ETF report for OUSA